EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY 4.0

Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison

Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, Stefano Vecchia, Luca Cancanelli, Vera Damuzzo, Stefania Gori, Roberto Tessari, Teodoro Sava, Alessandro Inno

Frontiers in Oncology · 29.06.2026 · 16

DOI: 10.3389/fonc.2026.1883614 ↗

Kurz gefasst

Korrektur in der Zeitschrift Frontiers in Oncology, online erschienen am 29.06.2026. Verfasst von Luna Del Bono und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Specialization in Hospital Pharmacy, Department of Pharmacy, University of Pisa, Pisa, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

EGFR-mutated NSCLCamivantamabfirst-line therapyindirect treatment comparisonlazertinibnetwork meta-analysisosimertinibreconstructed individual patient data

Autor:innen und Institutionen

  • School of Specialization in Hospital Pharmacy, Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Territorial Pharmaceutical Service, Azienda Unità Locale Socio-Sanitaria (ULSS) 8 Berica, Vicenza, Italy.
  • Italian Society of Clinical Pharmacy and Therapeutics, Turin, Italy.
  • Pharmaceutical Department, Unità Sanitaria Locale (USL) Toscana Centro, Prato, Italy.
  • Hospital Pharmacy Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
  • Hospital Pharmacy Department, Azienda Ulss 2 Marca Trevigiana, Treviso, Italy.

Zitieren

APA

Del Bono, L., Ossato, A., Gasperoni, L., Vecchia, S., Cancanelli, L., Damuzzo, V., Gori, S., Tessari, R., Sava, T., & Inno, A. (2026). Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1883614

Vancouver

Del Bono L, Ossato A, Gasperoni L, Vecchia S, Cancanelli L, Damuzzo V, et al. Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1883614

BibTeX
@article{DelBono2026,
  author = {Del Bono, Luna and Ossato, Andrea and Gasperoni, Lorenzo and Vecchia, Stefano and Cancanelli, Luca and Damuzzo, Vera and Gori, Stefania and Tessari, Roberto and Sava, Teodoro and Inno, Alessandro},
  title = {Correction: Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1883614}
}
Kostenlos starten →